Stereotactic lung reirradiation for local relapse: A case series.

Lung cancer Lung reirradiation SBRT reirradiation Stereotactic treatment

Journal

Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416

Informations de publication

Date de publication:
May 2021
Historique:
received: 18 02 2021
revised: 17 03 2021
accepted: 28 03 2021
entrez: 29 4 2021
pubmed: 30 4 2021
medline: 30 4 2021
Statut: epublish

Résumé

Local recurrence after lung SBRT for early stage NSCLC is rare but its treatment remains a challenge due to limited surgical options. We report a case series of 5 patients treated by stereotactic lung salvage reirradiation for local relapse after a previous lung SBRT. Included patients presented an isolated primary lung relapse within at least the 50% isodose of the previous SBRT treatment. Typical reirradiation schedule was 60 Gy in 8 fractions at isodose 80% and was delivered by Cyberknife® using Synchrony® fiducial tracking system. Dose summations were performed to evaluate the safety of the reirradiation. We identified 5 patients presenting peripheral lesions. All reirradiated lesions were locally controlled after a median follow-up of 11.1 months (6,7-12,2), while PFS at 6 months was 60% (n = 3). We did not notice any Grade 3 or more acute or late adverse event. We observed encouraging short-term outcome of lung SBRT reirradiation in patients presenting isolated local relapse of an early-stage NSCLC. Further studies are necessary to confirm the safety and efficiency of this salvage treatment approach.

Identifiants

pubmed: 33912693
doi: 10.1016/j.ctro.2021.03.007
pii: S2405-6308(21)00033-1
pmc: PMC8065183
doi:

Types de publication

Journal Article

Langues

eng

Pagination

85-87

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1387-93
pubmed: 20381271
Sci Rep. 2021 Feb 25;11(1):4590
pubmed: 33633130
Lung Cancer. 2015 Jul;89(1):50-6
pubmed: 25997421
Radiat Oncol. 2014 Sep 19;9:210
pubmed: 25239200
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):819-27
pubmed: 25220718
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):462-469
pubmed: 29353658
Int J Clin Oncol. 2005 Aug;10(4):247-50
pubmed: 16136369
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):402-6
pubmed: 25017480
J Thorac Oncol. 2017 Feb;12(2):281-292
pubmed: 27826034
BMC Cancer. 2019 Apr 3;19(1):305
pubmed: 30943943
J Thorac Oncol. 2015 Aug;10(8):e69-71
pubmed: 26200281
Front Oncol. 2020 Aug 11;10:1577
pubmed: 32850462
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Am J Clin Oncol. 2014 Feb;37(1):70-6
pubmed: 23357968

Auteurs

Rémy Kinj (R)

Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Alessio Casutt (A)

Department of Pulmonology, Lausanne University Hospital, Lausanne, Switzerland.

Alexander Bennassi (A)

Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Hasna Bouchaab (H)

Department of Medical Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Véronique Vallet (V)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Alban Lovis (A)

Department of Pulmonology, Lausanne University Hospital, Lausanne, Switzerland.

Mahmut Ozsahin (M)

Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Classifications MeSH